Evidence map›Paper›PMID 32101580›Full record

ArticlePloS one2020

Low enrollment and high treatment success in children with drug-resistant tuberculosis in Ethiopia: A ten years national retrospective cohort study.

Habteyes Hailu Tola, Kourosh Holakouie-Naieni, Mohammad Ali Mansournia, Mehdi Yaseri, Ephrem Tesfaye, Zemedu Mahamed, Million Molla Sisay

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Habteyes Hailu TolaDepartment of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), School of Public Health, Tehran, Iran.
Kourosh Holakouie-NaieniDepartment of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), School of Public Health, Tehran, Iran.ORCID 0000-0003-0623-7503
Mohammad Ali MansourniaDepartment of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), School of Public Health, Tehran, Iran.
Mehdi YaseriDepartment of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), School of Public Health, Tehran, Iran.ORCID 0000-0002-4066-873X
Ephrem TesfayeTuberculosis/HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Zemedu MahamedTuberculosis/HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Million Molla SisaySaint Peter's Specialized Hospital, Research and Evidence Generation Directorate, Addis Ababa, Ethiopia.ORCID 0000-0002-2021-8440
Ethiopian Public Health Institute · ETTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited evidence exists on the treatment outcome and factors that are associated with the duration from the initiation of treatment to death or treatment failure in children with drug resistant tuberculosis (DR-TB). Thus, we aimed to determine the proportion of treatment enrollment, status of treatment outcome and determine factors that are associated with the duration from treatment initiation to death or treatment failure in children treated for DR-TB in Ethiopia.

methodsWe conducted a retrospective cohort study in children younger than 15 years old who were treated for DR-TB from February 2009 to February 2019 in Ethiopia. We collected data on socio-demographic and clinical characteristics from clinical charts, registration books and laboratory result reports on 155 children. Proportion of enrollment to the treatment was calculated by dividing the total number of children who were receiving the treatment by the total number of DR-TB patients treated during the specified years. We used Cox proportional hazard models to determine factors that were associated with the duration from the beginning of the treatment to death or treatment failure. Data was analyzed using STATA version 14.

resultsOf the 3,478 DR-TB patients enrolled into the treatment and fulfilling our inclusion criteria during the past ten years, 155 (4.5%) were children. Of the 155 children, 75 (48.4%) completed the treatment and 51 (32.9%) were cured. Furthermore, 18 (11.6%) children were died, seven (4.5%) lost to follow up and treatment of four (2.6%) children was failed. The overall treatment success was 126 (81.3%). Age younger than 5 years old [Adjusted Hazard Ratio (AHR) = 3.2, 95%CI (1.2-8.3)], HIV sero-reactivity [AHR = 5.3, 95%CI (1.8-14.9)] and being anemic [AHR = 4.3, 95%CI (1.8-10.3)] were significantly associated with the duration from the enrollment into the treatment to death or treatment failure.

conclusionIn this study, the proportion of children enrolled into DR-TB treatment was lower than the proportion of adults enrolled to the treatment (4.5% in children versus 95.5% in adults) in last ten years. Our findings also suggest that children with DR-TB can be successfully treated with standardized long term regimen. Further prospective cohort study is required to investigate factors contributing to death or treatment failure.

Indexed as

AdolescentAntitubercular AgentsChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantMaleMycobacterium tuberculosisPatient ParticipationRetrospective StudiesTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID32101580
PMCPMC7043800
OpenAlexW3007670454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.